The N.J.-based pharma launched a late-stage trial of its drug candidate for Alzheimer's disease, challenging Eli Lilly's (LLY) solanezumab to be first to market. Earlier studies of Merck's (MRK) MK-8931 drug showed it prevents formation of new biomarkers associated with Alzhei-mer's. Bapineuzumab, the Alzhei-mer's candidate from Johnson & Johnson (JNJ), Pfizer (PFE) and Elan (ELN), failed to show clinical benefit. Merck shares rose 0.3% to 44.44.
- Pharmaceuticals & Drug Trials